948 related articles for article (PubMed ID: 15577140)
1. [Which is the better choice, estrogen or SERMs in postmenopausal women?].
Shintani M
Clin Calcium; 2004 Oct; 14(10):105-10. PubMed ID: 15577140
[TBL] [Abstract][Full Text] [Related]
2. [Raloxifene (Celvista, Evista)].
Body JJ; Sternon J
Rev Med Brux; 2000 Feb; 21(1):35-41. PubMed ID: 10748686
[TBL] [Abstract][Full Text] [Related]
3. Raloxifene reduces risk of vertebral fractures [corrected] in postmenopausal women regardless of prior hormone therapy.
Johnell O; Cauley JA; Kulkarni PM; Wong M; Stock JL
J Fam Pract; 2004 Oct; 53(10):789-96. PubMed ID: 15469774
[TBL] [Abstract][Full Text] [Related]
4. [SERM & bone metabolism: protective effects of SERM against fracture risk and its long-term beneficial effects].
Inaba M
Clin Calcium; 2004 Oct; 14(10):27-31. PubMed ID: 15577128
[TBL] [Abstract][Full Text] [Related]
5. [Effects of raloxifene on bone loss and fracture risk in the menopausal woman].
Vignot E; Meunier PJ
Contracept Fertil Sex; 1999 Dec; 27(12):858-60. PubMed ID: 10676043
[TBL] [Abstract][Full Text] [Related]
6. [Raloxifene (Evista) in the treatment of postmenopausal osteoporosis--the profile of the patient].
Kastelan D; Korsić M
Reumatizam; 2005; 52(2):67-70. PubMed ID: 16689133
[TBL] [Abstract][Full Text] [Related]
7. Prevention of osteoporosis and uterine effects in postmenopausal women taking raloxifene for 5 years.
Jolly EE; Bjarnason NH; Neven P; Plouffe L; Johnston CC; Watts SD; Arnaud CD; Mason TM; Crans G; Akers R; Draper MW
Menopause; 2003; 10(4):337-44. PubMed ID: 12851517
[TBL] [Abstract][Full Text] [Related]
8. Relationship between bone mass, invasive breast cancer incidence and raloxifene therapy in postmenopausal women with low bone mass or osteoporosis.
Burshell AL; Song J; Dowsett SA; Mershon JL; Delmas PD; Secrest RJ; Cauley JA
Curr Med Res Opin; 2008 Mar; 24(3):807-13. PubMed ID: 18254988
[TBL] [Abstract][Full Text] [Related]
9. Rationale for using raloxifene to prevent both osteoporosis and breast cancer in postmenopausal women.
Lee WL; Chao HT; Cheng MH; Wang PH
Maturitas; 2008 Jun; 60(2):92-107. PubMed ID: 18534794
[TBL] [Abstract][Full Text] [Related]
10. Relationships between bone mineral density and incident vertebral fracture risk with raloxifene therapy.
Sarkar S; Mitlak BH; Wong M; Stock JL; Black DM; Harper KD
J Bone Miner Res; 2002 Jan; 17(1):1-10. PubMed ID: 11771654
[TBL] [Abstract][Full Text] [Related]
11. Raloxifene. Not better than estrogen.
Can Fam Physician; 2000 Aug; 46():1592-6, 1599-603. PubMed ID: 10955178
[TBL] [Abstract][Full Text] [Related]
12. Comparison of fracture, cardiovascular event, and breast cancer rates at 3 years in postmenopausal women with osteoporosis.
Silverman SL; Delmas PD; Kulkarni PM; Stock JL; Wong M; Plouffe L
J Am Geriatr Soc; 2004 Sep; 52(9):1543-8. PubMed ID: 15341559
[TBL] [Abstract][Full Text] [Related]
13. Who will benefit from treatment with selective estrogen receptor modulators (SERMs)?
Sambrook P
Best Pract Res Clin Rheumatol; 2005 Dec; 19(6):975-81. PubMed ID: 16301191
[TBL] [Abstract][Full Text] [Related]
14. [Raloxifene in postmenopausal women].
Trémollières F; Ribot C
Gynecol Obstet Fertil; 2006 Feb; 34(2):147-53. PubMed ID: 16483822
[TBL] [Abstract][Full Text] [Related]
15. [Selective estrogen receptor modulators (SERMs)].
Matsumoto T
Clin Calcium; 2006 Sep; 16(9):1520-25. PubMed ID: 16951478
[TBL] [Abstract][Full Text] [Related]
16. [Defining the role of raloxifene as a therapeutic agent for postmenopausal osteoporosis: focus on its pharmacological properties].
Ohta H
Clin Calcium; 2004 Oct; 14(10):73-80. PubMed ID: 15577135
[TBL] [Abstract][Full Text] [Related]
17. Selective estrogen receptor modulators and postmenopausal health.
Roe EB; Chiu KM; Arnaud CD
Adv Intern Med; 2000; 45():259-78. PubMed ID: 10635051
[TBL] [Abstract][Full Text] [Related]
18. [Lasofoxifene, a next generation estrogen receptor modulator: preclinical studies].
Maeda T; Ke HZ; Simmons H; Thompson D
Clin Calcium; 2004 Oct; 14(10):85-93. PubMed ID: 15577137
[TBL] [Abstract][Full Text] [Related]
19. [Effects of estrogen and selective estrogen receptor modulators on osteoporosis].
Urano T
Clin Calcium; 2005 Apr; 15(4):591-5. PubMed ID: 15802770
[TBL] [Abstract][Full Text] [Related]
20. Raloxifene: new preparation. Not better than oestrogen.
Prescrire Int; 1999 Dec; 8(44):165-7. PubMed ID: 11503811
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]